

Marco Floridaia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9082244/publications.pdf>

Version: 2024-02-01

121
papers

2,185
citations

257450

24
h-index

276875

41
g-index

122
all docs

122
docs citations

122
times ranked

3097
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa. New England Journal of Medicine, 2014, 371, 234-247.	27.0	178
2	Clinical Characteristics of Hospitalized Individuals Dying With COVID-19 by Age Group in Italy. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 1796-1800.	3.6	138
3	Prevalence and Characteristics of Multinucleoside-Resistant Human Immunodeficiency Virus Type 1 among European Patients Receiving Combinations of Nucleoside Analogues. Antimicrobial Agents and Chemotherapy, 2000, 44, 2109-2117.	3.2	101
4	Gender differences in the treatment of HIV infection. Pharmacological Research, 2008, 58, 173-182.	7.1	89
5	Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Lancet, The, 2006, 368, 287-298.	13.7	83
6	Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial. Lancet HIV, the, 2017, 4, e341-e348.	4.7	71
7	Saquinavir. Clinical Pharmacokinetics, 1998, 34, 189-201.	3.5	66
8	Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. British Journal of Clinical Pharmacology, 2006, 62, 309-315.	2.4	57
9	Treatment with Protease Inhibitors and Coinfection with Hepatitis C Virus Are Independent Predictors of Preterm Delivery in HIV-Infected Pregnant Women. Journal of Infectious Diseases, 2007, 195, 913-914.	4.0	56
10	Differences in the clinical characteristics of COVID-19 patients who died in hospital during different phases of the pandemic: national data from Italy. Aging Clinical and Experimental Research, 2021, 33, 193-199.	2.9	49
11	Effect of sex, age and transmission category on the progression to AIDS and survival of zidovudine-treated symptomatic patients. Aids, 1995, 9, 51-56.	2.2	46
12	A Randomized, Double-Blind Trial on the Use of a Triple Combination Including Nevirapine, a Nonnucleoside Reverse Transcriptase HIV Inhibitor, in Antiretroviral-Naïve Patients With Advanced Disease. Journal of Acquired Immune Deficiency Syndromes, 1999, 20, 11-19.	0.3	43
13	Tuberculosis Case Finding With Combined Rapid Point-of-Care Assays (Xpert MTB/RIF and Determine TB) Tj ETQq1 1 0.784314 rgBT /O Diseases, 2017, 65, 1878-1883.	5.8	42
14	Diagnosis of HIV infection in pregnancy: data from a national cohort of pregnant women with HIV in Italy. Epidemiology and Infection, 2006, 134, 1120-1127.	2.1	41
15	Survival of zidovudine-treated patients with AIDS compared with that of contemporary untreated patients. Italian Zidovudine Evaluation Group. JAMA - Journal of the American Medical Association, 1992, 267, 1232-1236.	7.4	41
16	Antiretroviral Treatment in Pregnancy: A Six-Year Perspective on Recent Trends in Prescription Patterns, Viral Load Suppression, and Pregnancy Outcomes. AIDS Patient Care and STDs, 2009, 23, 513-520.	2.5	39
17	AIDS dementia complex in the Italian National AIDS Registry: temporal trends (1987-93) and differential incidence according to mode of transmission of HIV-1 infection. Journal of the Neurological Sciences, 1996, 144, 107-113.	0.6	38
18	Birth defects in a national cohort of pregnant women with <sc>HIV</sc> infection in <sc>Italy</sc>, 2001-2011. BJOG: an International Journal of Obstetrics and Gynaecology, 2013, 120, 1466-1476.	2.3	34

#	ARTICLE	IF	CITATIONS
19	Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2050-2052.	3.0	33
20	Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1027-1030.	3.0	32
21	Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 47-57.	9.1	32
22	Peripheral neuropathy in HIV patients in sub-Saharan Africa failing first-line therapy and the response to second-line ART in the EARNEST trial. <i>Journal of NeuroVirology</i> , 2016, 22, 104-113.	2.1	27
23	Raltegravir Plasma Concentrations in Treatment-Experienced Patients Receiving Salvage Regimens Based on Raltegravir with and without Maraviroc Coadministration. <i>Annals of Pharmacotherapy</i> , 2010, 44, 838-843.	1.9	26
24	Sex differences in clinical phenotype and transitions of care among individuals dying of COVID-19 in Italy. <i>Biology of Sex Differences</i> , 2020, 11, 57.	4.1	25
25	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. <i>New Microbiologica</i> , 2012, 35, 113-59.	0.1	25
26	Quality of life outcomes of combination zidovudine+didanosine+nevirapine and zidovudine+didanosine for antiretroviral-naïve advanced HIV-infected patients. <i>Aids</i> , 2000, 14, 2567-2574.	2.2	24
27	HIV-related morbidity and mortality in patients starting protease inhibitors in very advanced HIV disease (CD4 count of < 50 cells/uL): an analysis of 338 clinical events from a randomized clinical trial*. <i>HIV Medicine</i> , 2002, 3, 75-84.	2.2	22
28	Effectiveness of a Prevention of Mother-to-Child HIV Transmission Programme in an Urban Hospital in Angola. <i>PLoS ONE</i> , 2012, 7, e36381.	2.5	22
29	Treatment Change in Pregnancy Is a Significant Risk Factor for Detectable HIV-1 RNA in Plasma at End of Pregnancy. <i>HIV Clinical Trials</i> , 2010, 11, 303-311.	2.0	21
30	The Effects of AZT and DDI on Pre- and Postimplantation Mammalian Embryos: An In Vivo and In Vitro Study. <i>AIDS Research and Human Retroviruses</i> , 1992, 8, 639-649.	1.1	20
31	HCV+HIV coinfecting pregnant women: data from a multicentre study in Italy. <i>Infection</i> , 2016, 44, 235-242.	4.7	19
32	Nonrespiratory Complications and Obesity in Patients Dying with COVID-19 in Italy. <i>Obesity</i> , 2021, 29, 20-23.	3.0	19
33	Relationship Between Health-Related Quality of Life Measures and High HIV Viral Load in HIV-Infected Triple-Class-Experienced Patients. <i>HIV Clinical Trials</i> , 2014, 15, 176-183.	2.0	18
34	Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/mm ³). <i>HIV Medicine</i> , 2004, 5, 1-10.	2.2	17
35	Clinical characteristics of individuals with Down syndrome deceased with COVID-19 in Italy: A case series. <i>American Journal of Medical Genetics, Part A</i> , 2020, 182, 2964-2970.	1.2	17
36	Successful prevention of HIV mother-to-child transmission with dolutegravir-based combination antiretroviral therapy in a vertically infected pregnant woman with multiclass highly drug-resistant HIV-1. <i>Aids</i> , 2015, 29, 2534-2537.	2.2	16

#	ARTICLE	IF	CITATIONS
37	Differential survival of patients with AIDS according to the 1987 and 1993 CDC case definitions. JAMA - Journal of the American Medical Association, 1994, 271, 1197-1199.	7.4	15
38	Pregnancy and HIV infection: A european consensus on management. Aids, 2002, 16 Suppl 2, S1-18.	2.2	15
39	Antiretroviral Therapy at Conception in Pregnant Women with HIV in Italy: Wide Range of Variability and Frequent Exposure to Contraindicated Drugs. Antiviral Therapy, 2006, 11, 941-946.	1.0	15
40	Health-Related Quality of Life Outcomes in HIV-Infected Patients Starting Different Combination Regimens in a Randomized Multinational Trial: The INITIO-QoL Substudy. AIDS Research and Human Retroviruses, 2007, 23, 1215-1222.	1.1	14
41	Voluntary pregnancy termination among women with HIV in the HAART era (2002â€“2008): a case series from a national study. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2010, 22, 50-53.	1.2	14
42	Amniocentesis and chorionic villus sampling in HIVâ€“infected pregnant women: a multicentre case series. BJOG: an International Journal of Obstetrics and Gynaecology, 2017, 124, 1218-1223.	2.3	14
43	Plasma HIV-1 copy number and in vitro infectivity of plasma prior to and during combination antiretroviral treatment ¹ . Antiviral Research, 2000, 47, 189-198.	4.1	13
44	Efficacy of highly active antiretroviral therapy in HIVâ€“infected, institutionalized orphaned children in Tanzania. Acta Paediatrica, International Journal of Paediatrics, 2007, 96, 1090-1094.	1.5	13
45	A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease. Journal of Antimicrobial Chemotherapy, 2008, 62, 1356-1364.	3.0	13
46	Hematological effects of zidovudine prophylaxis in newborn infants with and without prenatal exposure to zidovudine. Journal of Medical Virology, 2011, 83, 551-556.	5.0	13
47	Pregnancy Outcomes in Women with Advanced HIV Infection in Italy. AIDS Patient Care and STDs, 2011, 25, 639-645.	2.5	13
48	Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study. Journal of Antimicrobial Chemotherapy, 2014, 69, 1377-1384.	3.0	13
49	Hospitalizations and Costs of Treatment for Protease Inhibitor-Based Regimens in Patients with Very Advanced HIV-Infection (CD4 < 50/mm ³). HIV Clinical Trials, 2000, 1, 9-16.	2.0	12
50	Lipid Profile During Pregnancy in HIV-Infected Women. HIV Clinical Trials, 2006, 7, 184-193.	2.0	12
51	Efficacy and Safety of Atazanavir in Patients with End-Stage Liver Disease. Infection, 2009, 37, 250-255.	4.7	12
52	Factors Influencing Gestational Age-Adjusted Birthweight in a National Series of 600 Newborns from Mothers with HIV. HIV Clinical Trials, 2008, 9, 287-297.	2.0	11
53	Rate, Predictors, and Consequences of Late Antenatal Booking in a National Cohort Study of Pregnant Women With HIV in Italy. HIV Clinical Trials, 2014, 15, 104-115.	2.0	11
54	Delayed diagnosis and treatment of tuberculosis in HIV+ patients in Mozambique: A cost-effectiveness analysis of screening protocols based on four symptom screening, smear microscopy, urine LAM test and Xpert MTB/RIF. PLoS ONE, 2018, 13, e0200523.	2.5	11

#	ARTICLE	IF	CITATIONS
55	Pregnancy and neonatal outcomes in women with HIV-1 exposed to integrase inhibitors, protease inhibitors and non-nucleoside reverse transcriptase inhibitors: an observational study. <i>Infection</i> , 2020, 48, 249-258.	4.7	11
56	Comorbidity status of deceased COVID-19 in-patients in Italy. <i>Aging Clinical and Experimental Research</i> , 2021, 33, 2361-2365.	2.9	11
57	Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors. <i>International Journal of STD and AIDS</i> , 2012, 23, 459-463.	1.1	10
58	Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1479-1485.	3.0	10
59	Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 193-199.	3.0	10
60	A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection. <i>Antiviral Therapy</i> , 1996, 1, 129-40.	1.0	10
61	A Randomized Trial Comparing the Introduction of Ritonavir or Indinavir in 1251 Nucleoside-Experienced Patients with Advanced HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1809-1820.	1.1	9
62	Early changes in adipokine levels and baseline limb fat may predict HIV lipodystrophy over 2 years following initiation of antiretroviral therapy [*] . <i>HIV Medicine</i> , 2008, 9, 101-110.	2.2	9
63	Potential anti-inflammatory effects of maraviroc in HIV-positive patients: A pilot study of inflammation, endothelial dysfunction, and coagulation markers. <i>Scandinavian Journal of Infectious Diseases</i> , 2014, 46, 466-470.	1.5	9
64	Rate and Determinants of Residual Viremia in Multidrug-Experienced Patients Successfully Treated with Raltegravir-Based Regimens. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 71-77.	1.1	9
65	Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, 1184-1192.	5.8	9
66	Plasma levels of CRP, neopterin and IP-10 in HIV-infected individuals with and without pulmonary tuberculosis. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2019, 16, 100107.	1.3	9
67	Epidemiological and Clinical Features of Pregnant Women with HIV: A 21-Year Perspective from a Highly Specialized Regional Center in Southern Italy. <i>HIV Clinical Trials</i> , 2008, 9, 36-42.	2.0	8
68	Trough Concentrations of Lopinavir, Nelfinavir, and Nevirapine With Standard Dosing in Human Immunodeficiency Virus-Infected Pregnant Women Receiving 3-Drug Combination Regimens. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 604-610.	2.0	8
69	Rate, correlates and outcomes of repeat pregnancy in HIV-infected women. <i>HIV Medicine</i> , 2017, 18, 440-443.	2.2	8
70	Growth indices in breastfed infants pre and postnatally exposed to tenofovir compared with tenofovir-unexposed infants. <i>Aids</i> , 2015, 30, 1.	2.2	8
71	Long-term follow-up of zidovudine therapy in asymptomatic HIV infection: results of a multicenter cohort study. The Italian Zidovudine Evaluation Group. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1994, 7, 31-8.	1.0	8
72	HIV-2 Infection, End-Stage Renal Disease and Protease Inhibitor Intolerance. <i>Clinical Drug Investigation</i> , 2011, 31, 345-349.	2.2	7

#	ARTICLE	IF	CITATIONS
73	Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease. BMC Infectious Diseases, 2011, 11, 341.	2.9	7
74	Use of Specific Antiretroviral Regimens Among HIV-Infected Women in Italy at Time of Conception: 2001â€“2011. AIDS Patient Care and STDs, 2012, 26, 439-443.	2.5	7
75	HIVâ€™ DNA dynamics and variations in HIVâ€™ DNA protease and reverse transcriptase sequences in multidrugâ€™resistant patients during successful raltegravirâ€™based therapy. Journal of Medical Virology, 2016, 88, 2115-2124.	5.0	7
76	HBV coinfection is associated with reduced CD4 response to antiretroviral treatment in pregnancy. HIV Clinical Trials, 2017, 18, 54-59.	2.0	7
77	A Randomized Trial (ISS 901) of Switching to Didanosine Versus Continued Zidovudine after the Diagnosis of AIDS. Journal of Acquired Immune Deficiency Syndromes, 1996, 12, 462-469.	0.3	7
78	Microbiologically confirmed infections and antibiotic-resistance in a national surveillance study of hospitalised patients who died with COVID-19, Italy 2020â€“2021. Antimicrobial Resistance and Infection Control, 2022, 11, .	4.1	7
79	A Randomized Trial (ISS 902) of Didanosine versus Zidovudine in Previously Untreated Patients with Mildly Symptomatic Human Immunodeficiency Virus Infection. Journal of Infectious Diseases, 1997, 175, 255-264.	4.0	6
80	Pregnancy outcomes and antiretroviral treatment in a national cohort of pregnant women with HIV: overall rates and differences according to nationality. BJOG: an International Journal of Obstetrics and Gynaecology, 2007, 114, 896-900.	2.3	6
81	Effect of HCV Infection on Glucose Metabolism in Pregnant Women with HIV Receiving HAART. HIV Clinical Trials, 2009, 10, 403-412.	2.0	6
82	Pregnancy care in two adolescents perinatally infected with HIV. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2009, 21, 796-798.	1.2	6
83	Declining HCV seroprevalence in pregnant women with HIV. Epidemiology and Infection, 2010, 138, 1317-1321.	2.1	6
84	Percentage and determinants of missed HIV testing in pregnancy: a survey of women delivering in the Lazio region, Italy. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2014, 26, 899-906.	1.2	6
85	Usefulness of calcaneal quantitative ultrasound stiffness for the evaluation of bone health in HIV-1-infected subjects: comparison with dual X-ray absorptiometry. HIV/AIDS - Research and Palliative Care, 2016, 8, 109.	0.8	6
86	Raltegravir, tenofovir, and emtricitabine in an HIV-Infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity. European Journal of Medical Research, 2010, 15, 81-3.	2.2	5
87	Rubella Susceptibility Profile in Pregnant Women with HIV. Clinical Infectious Diseases, 2011, 52, 960-962.	5.8	5
88	Levels of bone markers in a population of infants exposed in utero and during breastfeeding to tenofovir within an Option B+ programme in Malawi. Journal of Antimicrobial Chemotherapy, 2016, 71, 3206-3211.	3.0	5
89	Pregnancy Outcomes in HIV-Infected Women of Advanced Maternal Age. HIV Clinical Trials, 2013, 14, 110-119.	2.0	4
90	Impact of introducing subsidized combination treatment with artemether-lumefantrine on sales of anti-malarial monotherapies: a survey of private sector pharmacies in Huambo, Angola. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2016, 110, 588-596.	1.8	4

#	ARTICLE	IF	CITATIONS
91	Prevalence, Correlates and Outcomes of Smoking in Pregnant Women with HIV: A National Observational Study in Italy. Substance Use and Misuse, 2020, 55, 1165-1172.	1.4	4
92	Weight Gain during Pregnancy in Women with HIV Receiving Different Antiretroviral Regimens. Antiviral Therapy, 2020, 25, 315-325.	1.0	4
93	HIV-2 Infection, End-Stage Renal Disease and Protease Inhibitor Intolerance. Clinical Drug Investigation, 2011, , 1.	2.2	4
94	Common occurrence of anaemia at the end of pregnancy following exposure to zidovudine-free regimens. Journal of Infection, 2011, 63, 144-150.	3.3	3
95	Interindividual and Intra-Individual Variabilities of Darunavir and Ritonavir Plasma Trough Concentrations in Multidrug Experienced HIV Patients Receiving Salvage Regimens. Therapeutic Drug Monitoring, 2013, 35, 785-790.	2.0	3
96	Good prenatal detection rate of major birth defects in HIV-infected pregnant women in Italy. Prenatal Diagnosis, 2015, 35, 1374-1378.	2.3	3
97	Is "Option B+" Also Being Adopted in Pregnant Women in High-Income Countries? Temporal Trends From a National Study in Italy. Clinical Infectious Diseases, 2015, 60, 159-161.	5.8	3
98	Cytomegalovirus (CMV) DNA load in breast milk of human immunodeficiency virus-positive women and infant CMV infection acquisition are not reduced with long-term antiretroviral therapy. Clinical Microbiology and Infection, 2017, 23, 491-492.	6.0	3
99	Brief Report: Abacavir/Lamivudine and Tenofovir/Emtricitabine in Pregnant Women With HIV: Laboratory and Clinical Outcomes in an Observational National Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 99-104.	2.1	3
100	Atazanavir and darunavir in pregnant women with HIV: evaluation of laboratory and clinical outcomes from an observational national study. Journal of Antimicrobial Chemotherapy, 2018, 73, 1025-1030.	3.0	3
101	Lipodystrophy is an independent predictor of hypertriglyceridemia during pregnancy in HIV-infected women. Aids, 2006, 20, 944-947.	2.2	2
102	Plasma Lipid Profile in Pregnant Women with HIV Receiving Nevirapine. AIDS Patient Care and STDs, 2009, 23, 147-152.	2.5	2
103	Pregnancy outcomes and cytomegalovirus DNAemia in HIV-infected pregnant women with CMV. Clinical Microbiology and Infection, 2016, 22, 818-820.	6.0	2
104	Pregnant with HIV before age 25: data from a large national study in Italy, 2001-2016. Epidemiology and Infection, 2017, 145, 2360-2365.	2.1	2
105	HIV-1 Viral Load and Resistance in Genital Secretions in Patients Taking Protease-Inhibitor-Based Second-Line Therapy in Africa. Antiviral Therapy, 2018, 23, 191-195.	1.0	2
106	Evolving treatment implementation among HIV-infected pregnant women and their partners: results from a national surveillance study in Italy, 2001-2015. Journal of Global Health, 2017, 7, 010407.	2.7	2
107	Clinical characteristics of SARS-CoV-2 fully-vaccinated patients dying with COVID-19 in Italy. Clinical Microbiology and Infection, 2022, , .	6.0	2
108	HIV RNA viral Load and CD4 ⁺ T-cell Counts in HIV-Infected Pregnant Women with and without Treatment Discontinuation in Early Pregnancy. Antiviral Therapy, 2008, 13, 519-527.	1.0	2

#	ARTICLE	IF	CITATIONS
109	Resistance and Virological Response Analyses in a Three Initial Treatment Strategy Trial: A Substudy of the INITIO Trial. HIV Clinical Trials, 2009, 10, 385-393.	2.0	1
110	Glucose Plasma Levels and Pregnancy Outcomes in Women with HIV. HIV Clinical Trials, 2011, 12, 299-312.	2.0	1
111	Brief Report. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 452-455.	2.1	1
112	Full Viral Suppression, Low-Level Viremia, and Quantifiable Plasma HIV-RNA at the End of Pregnancy in HIV-Infected Women on Antiretroviral Treatment. AIDS Research and Human Retroviruses, 2015, 31, 673-678.	1.1	1
113	Vaginal delivery in women with HIV in Italy: results of 5 years of implementation of the national SICO-HIV protocol. Infection, 2019, 47, 981-990.	4.7	1
114	Prevalence and characteristics of symptomatic and asymptomatic tuboovarian masses in women with HIV: an ultrasonographic study. International Journal of STD and AIDS, 2010, 21, 472-476.	1.1	0
115	Body Mass Index and Weight Gain in Pregnant Women With HIV: A National Study in Italy. Clinical Infectious Diseases, 2013, 56, 1190-1193.	5.8	0
116	Serum Phosphate and Creatinine Levels in the First Year of Life in Infants Born to HIV-Positive Mothers Receiving Tenofovir-Based Combination Regimens During Pregnancy and Prolonged Breastfeeding in an Option B+ Program in Malawi. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, e90-e91.	2.1	0
117	Low mortality rates at two years in HIV-infected individuals undergoing systematic tuberculosis testing with rapid assays at initiation of antiretroviral treatment in Mozambique. International Journal of Infectious Diseases, 2020, 99, 386-392.	3.3	0
118	CD4/CD8 ratio in pregnant women with HIV and its association with pregnancy outcome: data from a national study in Italy. Infection, 2021, 49, 955-964.	4.7	0
119	Markers of microbial translocation during pregnancy: differences among HIV+ women of African and European provenance. Journal of Infection in Developing Countries, 2020, 14, 184-190.	1.2	0
120	Minimal prevalence of HPV vaccination and common occurrence of high-risk HPV types in pregnant women with HIV: data from a national study in Italy. European Journal of Clinical Microbiology and Infectious Diseases, 2022, 41, 505-509.	2.9	0
121	HIV RNA viral load and CD4+ T-cell counts in HIV-infected pregnant women with and without treatment discontinuation in early pregnancy. Antiviral Therapy, 2008, 13, 519-27.	1.0	0